Table 1 Patients characteristics, Gleason score, BMD categories of case and control groups, the mean BMD, decreasing trend of BMD pre- and post-ADT
From: Bone mineral density in Nigerian men on androgen deprivation therapy for advanced prostate cancer
Cases (n = 77) | Control n (77) | Total | Statistics | |
|---|---|---|---|---|
Age groups (years) | ||||
51–60 | 11 (14.3) | 13 (16.9) | 24 (15.6) | p = 0.283 |
61–70 | 32 (41.6) | 32 (41.6) | 64 (41.6) | |
71–80 | 28 (36.4) | 27 (35.1) | 55 (35.1) | |
81–90 | 6 (7.8) | 5 (6.5) | 11 (6.5) | |
Mean ± SD | 70.15 ± 6.7 | 68.92 ± 8.5 | ||
BMI | p = 0.578 | |||
< 18.5 | 4 (5.2) | 3 (3.9) | 7 (4.5) | |
18.5–24.9 | 48 (62.3) | 56 (72.7) | 104 (67.5) | |
25.0–29.9 | 19 (24.7) | 13 (16.9) | 32 (20.8) | |
≥ 30.0 | 6 (7.8) | 5 (6.5) | 11 (7.1) | |
BMD group | ||||
Normal (> − 1) | 43 (55.8) | 55 (71.4) | 98 (63.6) | |
Osteopenia (− 1 to − 2.5) | 23 (29.9) | 19 (24.7) | 42 (27.3) | p = 0.039 |
Osteoporosis (< − 2.5) | 11 (14.3) | 3 (3.9) | 14 (9.1) | |
Mean BMD T score | − 0.78 ± 1.7 | 0.26 ± 1.5 | p = 0.044 | |